Plus Therapeutics, Inc. (NASDAQ: PSTV) announced that its subsidiary CNSide Diagnostics has entered into a national coverage agreement with Humana Inc., effective October 29, 2025. The deal extends coverage of the CNSide Cerebrospinal Fluid Tumor Cell Enumeration (TCE) laboratory‑developed test to an additional 16 million people, bringing the total number of beneficiaries covered by the assay to 67 million across the United States.
Prior to the Humana agreement, CNSide had secured coverage with UnitedHealthcare that reached 51 million beneficiaries. The combined coverage now positions the assay as the most widely covered diagnostic for leptomeningeal metastases, giving Plus Therapeutics a national footprint that can accelerate test utilization and generate incremental revenue as the company prepares for a full U.S. launch later in 2025.
The CNSide CSF assay has demonstrated strong clinical performance, reporting 92 % sensitivity and 95 % specificity, and has influenced treatment decisions in 90 % of cases. Since 2020, more than 11,000 tests have been performed at over 120 institutions, underscoring real‑world adoption and validating the platform’s utility in routine clinical practice.
By expanding coverage, Plus Therapeutics strengthens the commercial foundation for its lead therapeutic candidate, REYOBIQ™. CEO Marc H. Hedrick noted that “the Humana agreement is a critical pathway for market penetration of the CNSide platform and a stronger foundation for future revenue growth from both diagnostics and the radiotherapeutic pipeline.” The broader reach also supports the company’s strategy to use diagnostic data to identify patients who may benefit from REYOBIQ’s targeted therapy.
Financially, the company reported a cash and investments balance of $16.6 million as of September 30, 2025, and received a $1.9 million advance from the Cancer Prevention & Research Institute of Texas as part of a $17.6 million grant. Plus Therapeutics has also secured a Nasdaq extension to regain compliance with the minimum bid price requirement, with a deadline of May 11, 2026.
The announcement was well received by investors, with Plus Therapeutics’ stock gaining 8.4 % in pre‑market trading on November 20. The market reaction was driven primarily by the expansion of coverage to 67 million beneficiaries, which is viewed as a significant commercial milestone that enhances the company’s revenue potential and supports its broader pipeline strategy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.